Arrhythmogenic potential of diuretic induced hypokalaemia in patients with mild hypertension and ischaemic heart disease

DONALD E STEWART, HAMID IKRAM, ERIC A ESPINER, M GARY NICHOLLS
From the Departments of Cardiology and Endocrinology, the Princess Margaret Hospital, Christchurch, New Zealand

SUMMARY In view of evidence suggesting an association of mild hypokalaemia with cardiac arrhythmia, the arrhythmogenic potentials of potassium losing and potassium sparing diuretic treatments were compared in a controlled prospective crossover study of 10 patients with mild hypertension and ischaemic heart disease. Mean (SEM) plasma potassium was 4.3(0.06) mmol/l and 3.3(0.07) mmol/l after potassium sparing and potassium losing treatments respectively. Blood pressure and volume depletion as assessed by weight change, plasma renin activity, and noradrenaline concentrations did not differ significantly in the two treatment periods. The potassium losing treatment phase was associated with an increased frequency of ventricular extrasystoles, a higher Lown grading during ambulatory electrocardiographic monitoring, prolonged duration and decreased phase 0 velocity of the monophasic action potential, a prolonged ventricular effective refractory period, and increased myocardial electrical instability as assessed by programmed ventricular stimulation.

It is concluded that minor changes in plasma potassium concentration are associated with increased ventricular electrical instability in patients with ischaemic heart disease. Mild hypokalaemia in such patients may predispose to life threatening arrhythmias and should be avoided.

Severe hypokalaemia (plasma potassium <3.0 mmol/l) is known to be associated with an increased incidence of cardiac arrhythmias.1-4 This risk is further enhanced by the coexistence of myocardial ischaemia, cardiac failure, and digitalis treatment.5-7 There have been several reports implicating hypokalaemia of this magnitude as a primary cause of sudden cardiac arrest.8-10 The clinical importance of less severe hypokalaemia associated with diuretic treatment (plasma potassium 3.0-3.5 mmol/l), however, remains controversial. Some authorities maintain that any degree of hypokalaemia should be avoided,11 whereas others state that only severe hypokalaemia warrants treatment.12-14 The controversy has been highlighted recently by the Multiple Risk Factor Intervention Trial15 and the re-analysis of the Oslo Study,16 both of which showed a greater incidence of sudden death in a subgroup of diuretic treated hypertensive patients with minor electrocardiographic changes than in patients who were not taking diuretics. The implication of this finding was that diuretic treatment may have increased the risk of fatal cardiac arrhythmias, presumably through potassium or magnesium deficiency. Such a possibility must remain speculative until it can be shown in prospective controlled studies that cardiac electrical instability is consistently associated with mild hypokalaemia.

We investigated cardiac electrical instability in patients with mild hypertension and known coronary artery disease during treatment with a potassium losing diuretic and again after a similar period of treatment on a potassium sparing diuretic. We assessed myocardial electrical instability by several techniques and used an inpatient crossover design to provide controlled data. Because of a possible role of increased sympathetic activity during volume depletion, changes in plasma catecholamine concentrations, as well as renin/angiotensin/aldosterone activity, were also studied.

Requests for reprints to Dr Hamid Ikram, Department of Cardiology, The Princess Margaret Hospital, Christchurch 2, New Zealand.

Accepted for publication 14 May 1985
Arrhythmogenic potential of diuretic induced hypokalaemia

Patients and methods

The protocol was approved by the ethical committee of the Canterbury Hospital Board and all patients signed a consent form after a full explanation of the procedures. Eleven patients were recruited from the outpatient department. Their clinical details are given in Table 1. We used the following inclusion criteria: (a) the presence of mild hypertension (supine diastolic pressure phase 5, 90–100 mm Hg) measured on two consecutive outpatient visits; (b) a clinical history of typical effort angina; and (c) absence of clinically manifest atrial arrhythmias. Patients with impaired renal function, potassium abnormalities before the start of the study, known hypersensitivity to thiazides or amiloride, and those who were pregnant were excluded.

Study design

The study followed a randomised crossover design and consisted of eight weeks' treatment with a potassium sparing diuretic and eight weeks' treatment with a potassium losing compound. Nine patients received amiloride 10 mg twice daily as the potassium sparing diuretic. One patient received spironolactone (Aldactone A) 25 mg twice daily because of nausea attributed to amiloride. Eight patients received chlorothalidone 25 mg twice daily as the potassium losing drug. Two patients with chlorothalidone intolerance received cyclopenthiazide 0.5 mg daily.

Five patients received the potassium sparing treatment first followed by the potassium losing treatment. In the remainder the order was reversed. When results were examined for an effect of treatment order none was found. Apart from sublingual nitrate for control of angina, no other drugs were used during the study. Nitrates were avoided for at least two hours before the blood pressure recording or any of the cardiac investigations described below.

Each eight week treatment phase ended with a 24 hour stay in hospital, during which a strict metabolic diet containing 180 mmol sodium and 60 mmol potassium was taken. Hormone, biochemical, and cardiac studies were carried out during these two inpatient periods as described below.

Cardiac investigations

Blood pressure was recorded by means of an automated version of the London School of Hygiene sphygmomanometer with patients supine at 1000 after a five minute period of rest and again after they had stood for two minutes. The diastolic blood pressure was taken as phase 5 of the Korotkoff sounds. One observer made all the recordings.

Ambulatory electrocardiograms were recorded on an Oxford Instruments Medilog two channel recorder for 24 hours. The recorded tape was played back on to paper by means of the American Edwards Co Eliminator playback unit. A complete disclosure of the entire tape was read manually by two independent observers, both of whom were unaware of the identity of each tape. Tapes were analysed for frequency of ventricular extrasystoles per hour and for grading on the Lown scale. Paired observations on the frequency of extrasystoles accorded to within 1% and there was complete agreement on Lown grades.

Exercise testing—A multistage treadmill stress test was performed during each hospital admission (Bruce protocol). End points for testing were ST depression on the electrocardiogram, the development of symptoms, or a heart rate greater than 90% of the predicted maximum.

Electrophysiological testing—The monophasic action potential was obtained by a close suction electrode (ABO Co, Tully, Sweden) positioned in the apex of the right ventricle and recorded on photographic paper at 100 mm/s simultaneously with a surface electrocardiogram. Ten consecutive action potentials were manually digitised by means of a Wang desk top computer. The maximum height of each action potential was standardised to 100%, and the action potential duration was measured at each 10% interval of amplitude. The relative slope of the upstroke was taken as the 90–10% upstroke time. The frequency response of

Table 1 Patient characteristics

<table>
<thead>
<tr>
<th>Case No</th>
<th>Age (yr)</th>
<th>Sex</th>
<th>Ejection fraction* (%)</th>
<th>Myocardial score†</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>63</td>
<td>M</td>
<td>49</td>
<td>7-4</td>
</tr>
<tr>
<td>2</td>
<td>48</td>
<td>M</td>
<td>64</td>
<td>8-0</td>
</tr>
<tr>
<td>3</td>
<td>55</td>
<td>M</td>
<td>40</td>
<td>5-4</td>
</tr>
<tr>
<td>4</td>
<td>60</td>
<td>F</td>
<td>82</td>
<td>10-6</td>
</tr>
<tr>
<td>5</td>
<td>56</td>
<td>M</td>
<td>79</td>
<td>10-2</td>
</tr>
<tr>
<td>6</td>
<td>60</td>
<td>F</td>
<td>73</td>
<td>0-0</td>
</tr>
<tr>
<td>7</td>
<td>63</td>
<td>M</td>
<td>70</td>
<td>9-6</td>
</tr>
<tr>
<td>8</td>
<td>51</td>
<td>F</td>
<td>56</td>
<td>7-6</td>
</tr>
<tr>
<td>9</td>
<td>57</td>
<td>M</td>
<td>62</td>
<td>2-0</td>
</tr>
<tr>
<td>10</td>
<td>52</td>
<td>M</td>
<td>60</td>
<td>6-4</td>
</tr>
<tr>
<td>11</td>
<td>58</td>
<td>M</td>
<td>71</td>
<td>6-4</td>
</tr>
<tr>
<td>Mean (SEM)</td>
<td>56(1-4)</td>
<td>64(3-8)</td>
<td>6*(1-0)</td>
<td></td>
</tr>
</tbody>
</table>

*Measured during left ventricular angiography.
†Scored according to the method of Brandt et al.25
the system was DC 800 Hz. We estimated the effective refractory period of the right ventricle and attempted induction of ventricular tachycardia with programmed extrastimuli. A bipolar pacing electrode was positioned in the apex of the right ventricle and up to three extrastimuli were applied after a train of eight paced beats for tachycardia induction. The effective refractory period was determined with a precision of 2 ms. The protocol was based on a previously published method in which a maximum of three extrastimuli, but no rapid ventricular pacing, was used. The degree of myocardial electrical instability was assessed in two ways: firstly by a modification of a previously described system that takes into account both the number of repetitive responses as well as the number of stimuli required to produce the responses; and, secondly, by the induction of a non-sustained ventricular tachycardia of at least three beats at a rate exceeding 100 beats/minute. Tachycardia induction was regarded as positive when the arrhythmia could be initiated in this way on three separate occasions.

**Hormonal and biochemical measurements** were undertaken on venous blood drawn at 0800 after an overnight fast and 12 hours of recumbency, and were repeated after 60 minutes of upright posture. Plasma aldosterone, adrenaline and noradrenaline, and angiotensin II concentrations and plasma renin activity were measured by standard techniques. Venous blood was also taken in the fasting state (0800) for measurement of plasma electrolyte concentrations. An arterial sample was drawn at the same time for blood gas and acid base determinations.

**Coronary angiography** was undertaken within three months of the study to assess the degree of coronary artery disease. A decrease of >50% in lumen diameter was taken to indicate significant stenosis. The coronary angiograms were scored by the method of Brandt et al. This system allocates a numerical weighting to various portions of the left ventricle depending on the extent of the vascular supply. The degree of narrowing of each vessel supplying the left ventricle is then graded and a score out of a maximum of 15 units calculated. This score provides a measure of the extent of myocardium affected by the coronary disease. Ejection fraction was calculated by digital callipers according to a previously described method.

**Results**

All but one patient completed the study without incident. The one exception was patient 11 (Table 1), who developed sustained ventricular tachycardia requiring DC shock during the electrophysiological study while in the potassium losing phase. He declined reinvestigation. Of the 11 patients, seven had abnormalities on the resting electrocardiogram recorded before the study. One showed voltage criteria for left ventricular hypertrophy, another had left anterior fascicular block, and in five there were non-specific T wave abnormalities.

**Coronary angiography**—Individual myocardial scores are given in Table 1. Five patients had single vessel disease, two had two vessel disease, and two had three vessel disease. One patient had only minor irregularities on the anterior descending coronary artery.

**Blood pressure** after diuretic treatment was not significantly different in the two groups. Mean lying pressure (mm Hg (SEM)) was 143(5-2) systolic and 86(2-3) diastolic after potassium sparing diuretics, and 135(3-4) systolic and 87(2-4) diastolic after potassium losing diuretics. Mean standing pressure was 135(4-9) systolic and 87(3-5) diastolic after potassium sparing diuretics, and 76(2-1) systolic and 81(3-8) diastolic after potassium losing diuretics.

**Plasma electrolyte concentrations** and biochemical indices (mean (SEM)) are given in Table 2. Plasma potassium concentration measured just before the study was 4-15(0-10) mmol/l. The plasma potassium

![Table 2](image-url)

<table>
<thead>
<tr>
<th>Index</th>
<th>Potassium losing phase</th>
<th>Potassium sparing phase</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Venous blood plasma (mmol/l):</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium</td>
<td>137(0-41)</td>
<td>137(0-47)</td>
<td>NS</td>
</tr>
<tr>
<td>Chloride</td>
<td>98(1-49)</td>
<td>108(0-38)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Carbon dioxide</td>
<td>27(0-5)</td>
<td>24(0-4)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Glucose</td>
<td>5-8(0-2)</td>
<td>5-7(0-4)</td>
<td>NS</td>
</tr>
<tr>
<td>Urea</td>
<td>5-7(0-3)</td>
<td>5-6(0-4)</td>
<td>NS</td>
</tr>
<tr>
<td>Creatinine</td>
<td>0-08(0-01)</td>
<td>0-09(0-01)</td>
<td>NS</td>
</tr>
<tr>
<td>Urate</td>
<td>0-42(0-03)</td>
<td>0-37(0-03)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Calcium</td>
<td>2-5(0-01)</td>
<td>2-4(0-03)</td>
<td>NS</td>
</tr>
<tr>
<td>Phosphate</td>
<td>0-9(0-07)</td>
<td>1-0(0-02)</td>
<td>NS</td>
</tr>
<tr>
<td>Arterial blood:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pH</td>
<td>7-39(0-01)</td>
<td>7-37(0-02)</td>
<td>NS</td>
</tr>
<tr>
<td>Bicarbonate (mmol/l)</td>
<td>23-4(0-51)</td>
<td>20-5(0-81)</td>
<td>&lt;0.02</td>
</tr>
<tr>
<td>Carbon dioxide (mm Hg)</td>
<td>38-5(1-0)</td>
<td>35-4(1-2)</td>
<td>&lt;0.02</td>
</tr>
</tbody>
</table>

NS, not significant.
Arrhythmogenic potential of diuretic induced hypokalaemia

The mean number of ventricular extrasystoles per hour recorded over 24 hours in nine patients during ambulatory monitoring while taking potassium losing and potassium sparing diuretics. Results are shown for individual patients and as mean (SEM).

Concentration was significantly lower (3.3(0.07) mmol/l) at the end of the potassium losing phase than at the end of the potassium sparing phase (plasma potassium 4.3(0.06) mmol/l (p<0.001). Total venous carbon dioxide and arterial bicarbonate values were significantly higher during the potassium losing phase. There was no significant difference between treatment phases in plasma sodium, glucose, creatinine, urea, calcium, magnesium, and phosphate concentrations, but plasma chloride was lower (p<0.05) and plasma urate was higher (p<0.05) during the potassium losing phase than during the potassium sparing phase (Table 2).

Ambulatory electrocardiography—Because of a tape failure in one study, paired data were obtained in only nine patients. There was a significantly greater (p<0.05) hourly frequency of ventricular extrasystoles and a higher Lown grade (p<0.05) during the potassium losing phase than during the potassium sparing phase (Fig. 1). In seven of nine studies, the frequency of ventricular extrasystoles was greater during the potassium losing phase (Fig. 1). The Lown grade was higher in five patients during the potassium losing phase, but in the remaining four cases it was similar during both treatments (Fig. 1). There was no apparent relation between the frequency of ventricular extrasystoles or Lown grading and plasma potassium concentration.

Exercise testing—Exercise tests were positive in five patients, two on the basis of 1 mm horizontal ST segment depression, and angina developed in three. The mean duration of exercise was not significantly different in the two intervention phases (470 s vs 435 s for the potassium losing and sparing phases respectively). Only two patients had ventricular...

Fig. 1  (a) Mean number of ventricular extrasystoles per hour recorded over 24 hours in nine patients during ambulatory monitoring while taking potassium losing and potassium sparing diuretics. Results are shown for individual patients and as mean (SEM). (b) Maximum Lown grade ventricular extrasystoles recorded during 24 hour ambulatory monitoring.

Fig. 2  Group mean time course of the monophasic action potential during potassium losing and potassium sparing treatment. p values were calculated by the paired t test.
extrasystoles during the exercise test. In both cases the ventricular extrasystoles occurred in the potassium losing phase and the same patients did not show any ventricular extrasystoles while taking the potassium sparing agents.

ELECTROPHYSIOLOGICAL STUDIES

_right ventricular monophasic action potential_—The slope of the action potential upstroke was significantly (p < 0.05) steeper during the potassium sparing phase. Action potential duration at 50% repolarisation was prolonged during the potassium losing phase but this difference was not statistically significant. Action potential duration at 90% repolarisation, however, was significantly prolonged by hypokalaemia (p < 0.001) (Fig. 2).

_right ventricular effective refractory period_—The effective refractory period of the right ventricle during the potassium losing phase was significantly prolonged (240(22) ms) compared with that during the potassium sparing phase (216(10-8) ms), (p < 0.05). The QT interval corrected for heart rate (0.45(0.03) s vs 0.44(0.02) s) showed a 2% prolongation in the potassium losing phase, but this change did not reach statistical significance.

_Tachycardia induction studies_—One patient developed sustained ventricular tachycardia requiring DC shock during the potassium losing phase. Because he refused to continue in the study he did not complete the potassium sparing phase. Data from the 10 paired studies are shown in Fig. 3. Four patients developed tachycardia and had higher myocardial electrical instability scores during the potassium losing phase than during potassium sparing phase. In all but one of the remaining patients the scores were the same with both treatment regimens. In one patient the score during the potassium sparing phase was slightly higher than that during the potassium losing phase. Non-sustained ventricular tachycardia was induced in five patients during the potassium losing phase and in three patients during the potassium sparing treatment phase.

**Heart rate**—Heart rate (mean (SEM)) in the potassium losing phase was 80.0(11.9) beats/min and 79.9...

![Fig. 3 Myocardial electrical instability score during potassium sparing and potassium losing treatment (see text for details of the scoring system).](image)

![Fig. 4 Plasma concentrations of aldosterone, angiotensin II, renin activity, and noradrenaline measured when patients were lying down or standing up while on potassium sparing and potassium losing therapy. Values are mean (SEM). Plasma aldosterone (both lying and standing values) was significantly higher (p < 0.001) during potassium sparing treatment.](image)
Arrhythmogenic potential of diuretic induced hypokalaemia

(11-0) beats/min during the potassium sparing phase.

HORMONE RESULTS
Hormone values when patients were lying or standing are shown in Fig. 4. Concentrations in supine patients and the rise in plasma noradrenaline and angiotensin II concentrations with erect posture were comparable in the two treatment phases. Plasma aldosterone, however, was significantly higher during treatment with potassium sparing diuretics (p<0-001). Although plasma renin activity was lower in this phase, the difference was not statistically significant.

Discussion
Although severe potassium deficiency may precipitate life threatening cardiac arrhythmias, the effect of less severe hypokalaemia, particularly in patients with ischaemic heart disease, is controversial.11 14 Recent studies have increased concern that conventional potassium losing diuretic treatment may be arrhythmogenic. The Medical Research Council mild hypertension study showed a significantly greater frequency of ventricular extrasystoles in patients treated with thiazide diuretics than in untreated control patients.27 Others have shown similar changes during thiazide treatment that were partly abolished by potassium repletion.11 12 Observations of an increased incidence of ventricular fibrillation after acute myocardial infarction in hypokalaemic patients28 29 and of increased incidence of sudden death associated with high dose diuretic treatment of patients with mild hypertension5 15 16 add further to the concern. Although there were several explanations for these findings, the possibility of a causal relation between diuretic treatment and increased mortality in certain subgroups of hypertensive patients requires urgent clarification. There are, however, practical problems. To show a causal relation between hypokalaemia and sudden death in a small subgroup of patients requires a very large scale trial.14 In the absence of this information, the case for preventing diuretic induced hypokalaemia must be based on appropriately designed and controlled electrical trials showing a consistent association of increased myocardial electrical instability with potassium losing treatment.

We have examined prospectively in a randomised crossover controlled trial the effect of two short term diuretic treatments (one associated with potassium sparing and the other associated with potassium loss) in patients with mild essential hypertension and ischaemic heart disease. The hypotensive effect, and the degree of volume depletion as judged by body weight, activity of the renin angiotensin system, and catecholamine concentrations were comparable with the two treatments. There were significant differences between the two treatments in plasma potassium, acid base, chloride and urate concentrations that accorded with the known actions of the diuretics. Plasma aldosterone was significantly higher in the potassium sparing phase as previously reported.30 More importantly, consistent electrophysiological changes occurred in all patients during the potassium losing phase, and there was evidence of increased cardiac electrical instability as measured by several different standardised techniques. While animal and in vitro studies have shown that severe hypokalaemia (plasma potassium <3-0 mmol/l) is associated with increased membrane potential negativity, increased rate of depolarisation, and increased duration of action potential11 32 the present study is the first to show that similar changes in action potential occur in man during modest changes in plasma potassium. Prolongation of action potential duration is indicative of delayed repolarisation. There was no significant difference between the two treatment phases at 50% repolarisation. This measurement includes phase 0, 1, and 2 of the action potential. Significant prolongation of the action potential was evident at 90% repolarisation during the potassium losing phase but not at 50%. This suggests that delayed repolarisation due to moderate hypokalaemia is mainly attributable to prolongation of phase 3 of the action potential. The action potential duration is heart rate dependent but rates during both treatment phases were identical; thus heart rate was not a factor responsible for the difference in delayed repolarisation in the potassium losing phase. Delayed repolarisation is usually estimated from the QT interval of the surface electrocardiogram. This is a measurement which is imprecise since it is often difficult to define the start and end of the QT segment in the surface electrocardiogram. There is no universal agreement on the choice of lead from which this measurement is to be made. In contrast to this the monophasic action potential can define the phases of excitation and repolarisation with a high degree of precision.33 These factors probably explain why we found more consistent and significant changes in the potassium losing phase from analysis of the monophasic action potential than from the QT segment measurement. A generalised electrophysiological effect of the potassium losing treatment is supported by lengthening of the effective refractory period of the right ventricle in every patient.

If delayed repolarisation is homogeneous it may exert an arrhythmogenic effect. Heterogeneous repolarisation, however, has been shown to be associated with an increased risk of serious ventricular arrhythmias in congenital syndromes,34 after myocardial infarction,35 and after certain drugs.36 To evaluate this effect further, we examined measures of cardiac electrical instability in patients at rest and during
exercise as well as during programmed intracardiac stimulation. From 24 hour recordings we found a significantly increased frequency of ventricular extrasystoles and a significantly higher Lown grading in the potassium losing phase—findings which are consistent with previous reports.  

Exercise induced ventricular extrasystoles occurred in only two of 20 studies and both patients were taking a potassium losing diuretic. This low frequency of ventricular extrasystoles during exercise (compared with that seen during ambulatory monitoring) is similar to previous reports.  

Although these results are consistent with increases in cardiac electrical instability associated with the potassium losing treatment, it is doubtful whether such findings alone constitute proof of increased susceptibility to life threatening arrhythmias. We therefore sought additional information by inducing tachycardia by programmed intracardiac stimulation—a technique which is regarded as a reliable predictor of serious arrhythmias. The electrical stability of the myocardium was assessed in two ways. Firstly, the frequency of induced ventricular tachycardia was measured, and secondly, we used a scoring system that takes into account both the number of repetitive responses as well as the number of stimuli required. Non-sustained ventricular tachycardia developed in five patients during the potassium losing phase and in three patients during the potassium sparing phase. In most patients the electrical instability score was similar for both diuretic treatments; thus overall there was no statistical difference between scores from the two phases of treatment. In those patients in whom there was a change (increase or decrease in score) electrical instability increased in four and decreased slightly in only one patient during the potassium losing phase of treatment.  

While our observations of increased myocardial electrical instability may be explicable on the basis of potassium depletion, other factors could be involved. In keeping with previous reports we found no correlation between plasma potassium concentration and indices of cardiac electrical instability. Despite the suggested importance of magnesium there were no significant differences in plasma magnesium between the two treatment phases. The possibility of diuretic induced hormonal changes, particularly in noradrenaline, contributing to increased electrical instability was investigated, with negative results. Further research is needed to evaluate the contribution of factors other than potassium.  

As recently emphasised, no single technique is yet available to identify patients at high risk of sudden cardiac death. Our study has examined myocardial electrical function in several ways and is not dependent on a single technique for its conclusions. The results show that diuretic induced changes in plasma potassium are associated with demonstrable electrophysiological changes in all patients, that most showed increased frequency and complexity of ventricular extrasystoles, and that some had exercise induced arrhythmias. A smaller number were more susceptible to ventricular arrhythmias elicited by intracardiac stimulation. These findings, obtained in a small number of carefully studied patients, seem to reflect the clinical situation in which most patients may well have electrophysiological changes, but only a small proportion have major or fatal arrhythmias. It should be noted that our patients were not a high risk group; none had extensive coronary artery disease, history of significant arrhythmia, cardiac failure, or use of digitalis or other cardioexcitatory drugs. Since it is easier to prevent potassium deficiency than to treat it, we conclude that a reduction in plasma potassium should be avoided in patients with ischaemic heart disease requiring diuretics.

We thank the Medical Research Council of New Zealand for financial support. Part of this study was undertaken when DES was in receipt of a grant from the Canterbury Medical Research Foundation.

References

10. Cembrowski GS, Huntington RW, 3rd. Probable fatal cardiac dysrhythmia secondary to diuretic-induced
Arrhythmogenic potential of diuretic induced hypokalaemia


Jones-Collins BA, Patterson RE. Quantitative measurement of electrical instability as a function of myocardial infarct size in the dog. Am J Cardiol 1981; 48: 858–63.


Nicholls MG, Espiner EA. A sensitive, rapid radioimmunoassay for angiotensin II. NZ Med J 1976; 83: 399–403.


Arrhythmogenic potential of diuretic induced hypokalaemia in patients with mild hypertension and ischaemic heart disease.

D E Stewart, H Ikram, E A Espiner and M G Nicholls

*Br Heart J* 1985 54: 290-297
doi: 10.1136/hrt.54.3.290

Updated information and services can be found at:
http://heart.bmj.com/content/54/3/290

These include:

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/